RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
A legfontosabb adatok
- Ki végzi
- Cabaletta Bio
- Hol
- Rome (Olaszország)A helyszín megnézéseMég 4 másik országban, 41 helyszínen
- Azonosító
- NCT06154252
- EU 2025-521145-24-01
- ISRCTN75158615
- Állapot
- Toboroz
- Fázis
- 2/3. fázis
- Résztvevők
- 74 fő, tervezett
- Kezdés
- 2023. dec. 20.
- Várható befejezés
- 2028. júl.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoport
- A vizsgált kezelések
- CABA-201 following preconditioning with fludarabine and cyclophosphamide
- A regiszteradat frissítve
- 2026. november 13.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults and children with active inflammatory muscle disease (idiopathic inflammatory myopathy) that stays active despite standard treatment. It tests CABA-201, a CAR T cell therapy made from the person's own immune cells.
- Életkor
- Adults: 18 to 75 years. Children: 6 to 17 years at enrollment.
- Nem
- All sexes can join.
- A betegség stádiuma
- A diagnosis of IIM based on the 2017 EULAR/ACR classification criteria. Adults must have DM, ASyS or IMNM and muscle weakness. The disease must be active, shown by raised muscle enzymes (such as CK), a DM rash, or signs on muscle biopsy, MRI or electromyography.
- Korábbi kezelés
- The disease must be active despite past or current standard treatment. People who already had CAR T cell therapy cannot join.
A részvétel fő kizáró okai
- Cannot have leukapheresis (collection of white blood cells)
- Past severe allergic reaction to fludarabine or cyclophosphamide
- Active infection needing treatment at screening
- Serious lung or heart problems, or other severe uncontrolled organ disease
- Past solid organ transplant or blood stem cell transplant
A regiszter feltételei, szó szerint
Mind a 25 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥18 and ≤75
- A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
- Diagnosis of DM, ASyS, or IMNM
- Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
- Presence of muscle weakness; Other protocol-defined criteria apply
- Age ≥6 and ≤17 years at enrollment
- A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
- Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated muscle enzymes, DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography; Other protocol-defined criteria apply
Ki nem vehet részt
- Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
- Previous CAR T cell therapy
- Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant; Other protocol-defined criteria apply; Juvenile Cohort
- Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
- Previous CAR T cell therapy
- Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant; Other protocol-defined criteria apply
- History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
- Active infection requiring medical intervention at screening
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections
- Significant lung or cardiac impairment
- History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
- Active infection requiring medical intervention at screening
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections
- Significant lung or cardiac impairment
- Contraindication to leukapheresis
- Contraindication to leukapheresis
Egyéb feltételek
- Adult Cohorts
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 6 és 75 év között vagy?
Helyszínek itt: Olaszország
Még 4 másik országban, 41 helyszínen
- Ospedale Pediatrico Bambino GesùRome, OlaszországToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
A vizsgálat 3 csoportja
- CABA-201 Phase 1/2A vizsgált kezelés
DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM. ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with ASyS. IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM. JIIM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with JIIM.
Kezelés: CABA-201 following preconditioning with fludarabine and cyclophosphamide
- CABA-201 Phase 2b - Sub-study 1A vizsgált kezelés
Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM and ASyS.
Kezelés: CABA-201 following preconditioning with fludarabine and cyclophosphamide
- CABA-201 Phase 2b - Sub-study 2A vizsgált kezelés
Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM.
Kezelés: CABA-201 following preconditioning with fludarabine and cyclophosphamide
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT06154252: ki vehet részt
- Publikációk
- Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I/II trial.Molecular therapy : the journal of the American Society of Gene Therapy, 2024
- A regiszteradat frissítve
- 2026. november 13.